New hope for PBC: drug aims to slow liver damage
NCT ID NCT07216235
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. About 386 adults who are already on standard treatment will receive either the drug or a placebo for a long period. The goal is to see if the drug can prevent serious liver events like decompensation, need for transplant, or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
saroglitazar magnesium
What this could lead to
If it works, this could provide a new treatment option to slow liver damage and reduce the need for transplant in people with primary biliary cholangitis.
What could go wrong
This is a late-stage trial, but it's still testing if the drug works better than placebo. There's no guarantee it will improve outcomes, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.